View clinical trials related to Kidney Transplantation.
Filter by:The goal of this observational study is to learn about the current status of illness perception and the distribution of coping styles in kidney transplant recipients. The main question clarifies the current status and experience of illness perception in post-transplant patients with different coping styles, and aims to provide a reference basis for intervention of illness perception in kidney transplant patients, with the aim of improving their current status of illness perception, optimizing their awareness of treatment management and self-care behaviors, and perfecting the modern medical service system. Participants will describe the main tasks participants will be asked to do.
The goal of this clinical trial is to evaluate cardiometabolic and inflammatory parameters in kidney transplant recipients after transitioning to a plant-based diet (PBD). The main aims of the study are as follows: - To test the feasibility of transiting renal allograft recipients who are > 3 months post-transplant to a PBD - To study the effect of a PBD on cardiometabolic parameters in kidney transplant recipients - To assess the effect of a PBD on peripheral blood Th17/Treg ratio and systemic inflammation in kidney transplant recipients Participants will be asked to: - Complete a 2-week investigator-designed PBD transition program - Follow a PBD for a minimum of 16 weeks - Consent for blood draws, urine samples, and fecal samples along with physical exams - Complete intermittent food frequency questionnaires and quality of life questionnaires - Periodically meet with investigators and other study participants Researchers will compare baseline measurements with future measurements for each participant.
This EmLina Renal trial is an investigator initiated, single-center, prospective, open-label, randomized clinical study to examine the safety and effect of empagliflozin 25 mg once a day vs. linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus. Glycemic variables will include fasting glucose and glycated hemoglobin (HbA1c). Renal outcomes will include change in eGFR, spot urine albumin-creatinine ratio (UACR) and spot urine protein-creatinine ratio (UPCR). Body composition variables will include total fat mass, fat percentage, total lean mass, and bone mineral content as measured by dual-energy X-ray absorptiometry (DEXA). Body composition will also be measured by BIA. The study will be conducted according to the CONSORT guidelines. The patient population for the trial will be derived from Medanta-The Medicity Hospital endocrine and nephrology out-patient clinic. The study will be conducted in Medanta-The Medicity Hospital, Gurugram, Haryana, which is a tertiary care center in North India. Patients deemed eligible will be screened for the trial
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher. Having a cPRA of 99.5% or higher means that your immune system would reject 99.5% of kidneys available for transplant. The study will test whether new products called Chimeric Antigen Receptor T Cells (CAR T Cells), when given with chemotherapy, is safe and will reduce cPRA. The main study will last up to 2 years: Participants will have up to 30 clinic or hospital visits over a one-year period. If a transplant takes place, there will be 9 more visits after transplant. Long term follow up is required by the Food and Drug Administration (FDA) for 15 years after receiving CAR T cell. The primary objective is to evaluate the safety and feasibility of administering CART BCMA + huCART-19 following lymphodepletion, including determination of optimal tolerated regimen (OTR) and/or recommended phase 2 regimen, according to the incidence of dose limiting toxicity (DLT) in highly sensitized patients awaiting kidney transplant.
The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients
This is a randomized controlled pragmatic clinical trial. We aim to evaluate the effect of Ringer lactate solution (RLS) and normal saline solution (NSS) on the electrolyte abnormality of kidney transplant recipients (KTR) during the first post-operative week. The problem with using NSS as a standard replacement fluid is the hyperchloremic metabolic acidosis which might compromise the kidney allograft function. A total 60 KTR will be enrolled and randomized to receive either RLS or NSS. The primary outcome is serum bicarbonate level at day 5 after transplantation. Secondary outcomes include the serum potassium, serum sodium, serum chloride, cytokine panel, and the incidence of delayed graft function.
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.
There are two main treatments for end-stage renal disease (ESRD): dialysis and transplantation.Renal transplantation is the best and most preferred treatment for ESRD patients.Self management after renal transplantation is difficult. Individuals need appropriate care,education, counseling and support in order to change their behavior to cope with health problems during the transplantation process.The aim of nursing care and education is to enable the individual to acquire the knowledge, skills and attitude to independently carry out daily life activities and to adopt this as a lifestyle.Nursing care and education requires an interdisciplinary teamwork, and in this process, the nurse plays a key role as she constantly interacts with the donor, recipient and family.The research was designed as a randomized controlled experimental study with pretest-posttest design.A total of 60 nurses, 30 in the control group and 30 in the intervention group,who met the criteria for inclusion in the study, will form the sample of the study.After obtaining consent from the nurses in the intervention and control groups, they will be asked to fill out the Nurse InformationForm, the Patient-Centered Care Competency Scale and the Nurses Counseling Skills Scale. Aftercompleting the web-based training, intervention group nurses will be asked to fill in the Patient Centered Care Competency Scale and the Counseling Skills in Nurses Scale at the 1st and 3rd months. No training will be given to the nurses in the control group and they will be asked to fill the Patient-Centered Care Competency Scale and the Counseling Skills for Nurses Scale again.
This prospective, single-arm, interventional study is designed to assess the short-term and long-term safety and efficacy of bilateral ultrasound renal sympathetic denervation (RDN) of the native kidneys in renal transplant patients with uncontrolled hypertension. Objectives: - To assess the short-term and long-term changes in ambulatory and office blood pressure (BP) following native kidney RDN in renal transplant patients - To assess the long-term safety of native kidney RDN in renal transplant patients - To assess the short-term and long-term change in antihypertensive drug prescriptions following native kidney RDN in renal transplant patients - To assess the short-term and long-term change in adherence to antihypertensive drugs following native kidney RDN in renal transplant patients
We will study a prospective cohort including all kidney transplant recipients undergoing kidney graft biopsy in one kidney transplantation center, for a duration of 5 years. Our primary outcome is to compare the number of circulating NK cells between patients and without humoral rejection. Our secondary outcomes are to describe the cellular, genetic, humoral, and histological characteristics of humoral rejection and their evolution.